This text was first revealed on The Motley Idiot’s U.S. web site.
Shares have been a wealth-creating machine for traders over the long term. Although different asset courses have delivered a optimistic nominal return to affected person traders, together with gold, oil, and housing, none have come near the annualized complete return shares have generated over the past century.
Whereas innovation is a key development driver on Wall Road, dividend investing has fueled this long-term outperformance.
Final yr, funding advisory agency Hartford Funds launched a report that examined the ins-and-outs of simply how superior dividend shares have been over lengthy durations, when in comparison with publicly traded firms that don’t supply a payout. In a collaboration with Ned Davis Analysis, Hartford Funds’ report (“The Energy of Dividends: Previous, Current, and Future”) discovered that dividend-paying shares had greater than doubled up the annualized returns of non-payers — 9.17% vs. 4.27% — over the earlier 50 years (1973-2023).
The wonderful thing about dividend investing is that tremendous offers can at all times be discovered. Among the finest locations to find clear-as-day earnings bargains hiding in plain sight is inside the benchmark S&P 500 (SNPINDEX: ^GSPC).
The S&P 500 is comprised of 500 of the biggest, time-tested, multinational companies traded on U.S. inventory exchanges. Roughly 80% of those 500 companies pays a daily dividend to their shareholders. Firms that pay a constant dividend are usually worthwhile on a recurring foundation and might present clear long-term development outlooks.
However no two dividend shares are created equally. The S&P 500 is comprised of simply over a dozen ultra-high-yield dividend shares — i.e. firms with yields which might be a minimum of 4 instances larger than the 1.335% yield of the S&P 500. Two of those ultra-high-yield S&P 500 dividend shares are nothing in need of screaming buys proper now.
Associated: Prime S&P 500 ETFs in Canada
Time to pounce: Pfizer (5.87% yield)
The primary high-octane S&P 500 dividend inventory that’s begging to be purchased by opportunistic earnings seekers is none apart from pharmaceutical colossus Pfizer (NYSE:PFE).
In late April, Pfizer’s inventory hit a decade-low of round $25 per share, which equated to a 59% decline from its all-time excessive that was achieved in the course of the COVID-19 pandemic in December 2021. This precipitous decline got here after a interval of immense working success for the corporate.
In the course of the pandemic, Pfizer was considered one of a really small variety of drug builders to have efficiently engineered a COVID-19 vaccine (generally known as Comirnaty), in addition to an oral remedy (generally known as Paxlovid) to minimize the severity of COVID-19 signs. Mixed gross sales of Comirnaty and Paxlovid have declined from a peak of greater than $56 billion in 2022 to an estimated $8 billion this yr. Having to soak up a $48 billion retracement in COVID-19 gross sales hasn’t sat nicely with Wall Road or traders.
But when earnings seekers dig beneath the floor and have a look at everything of Pfizer’s novel drug portfolio and pipeline, they’re going to discover a firm that’s meaningfully strengthened itself for the reason that decade started.
For instance, Pfizer’s huge drug portfolio, excluding its duo of COVID-19 therapies, has continued to develop. After delivering 7% working gross sales development (ex. COVID therapies) in 2023, the corporate’s COVID-excluded therapies grew by 11% on a constant-currency foundation in the course of the March-ended quarter.
So as to add to the above, a lot of Pfizer’s most-important therapies are breaking by means of new ceilings. Gross sales of blockbuster blood-thinning drug Eliquis topped the $2 billion within the March quarter, whereas its Vyndaqel household of merchandise loved operational gross sales development of 66% to $1.14 billion to start the yr.
One thing else traders want to think about is that Pfizer accomplished a $43 billion acquisition of cancer-drug developer Seagen in December. Though this acquisition is predicted to negatively affect earnings per share (EPS) within the present yr, price synergies, coupled with a vastly expanded oncology pipeline, ought to be meaningfully accretive to Pfizer’s EPS within the years to return. The shortsightedness of choose traders is giving affected person earnings seekers an unimaginable alternative to snag shares of Pfizer on a budget.
Talking of “low cost,” shares of Pfizer are buying and selling at roughly 10 instances forward-year earnings. This represents a 19% low cost to its common a number of to ahead earnings over the trailing-five-year interval.
The cherry on the sundae is that Pfizer confirmed its dividend, which is nearing a 6% yield, is completely secure. In accordance with Chief Monetary Officer David Denton, “Our No. 1 precedence from a capital allocation perspective is each supporting and rising our dividend over time — and that isn’t in danger.”
Time to pounce: Walgreens Boots Alliance (5.5% yield)
The second ultra-high-yield S&P 500 dividend inventory that earnings seekers can confidently pounce on proper now could be beaten-down pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA).
Whereas Pfizer has been a sufferer of its personal success, Walgreens’ inventory is most positively flailing due to its personal failures. Whereas not a complete record, Walgreens has been contending with:
- Rising on-line pharmacy competitors from the likes of Amazon (NASDAQ:AMZN).
- A difficult retail surroundings that’s not been helped by elevated shrinkage (i.e., theft) at a few of its shops.
- The expensive launch and growth of its healthcare companies operations, which resulted in a $5.8 billion write-down within the fiscal second quarter (ended Feb. 29, 2024).
- Ongoing authorized challenges which have included its function within the opioid disaster.
- A near-halving of its dividend from $0.48/quarter to $0.25/quarter to start the present calendar yr.
In different phrases, there are tangible the reason why Walgreens Boots Alliance has declined by 81% since its inventory hit an all-time closing excessive in 2015. The excellent news is that there seems to be mild on the finish of the tunnel for affected person traders.
The most important and most-needed change for Walgreens is that it introduced in Tim Wentworth as its new CEO in October. Wentworth has many years of expertise within the healthcare area, having beforehand served because the CEO of Specific Scripts, the biggest pharmacy-benefit supervisor within the U.S. Prior CEO Rosalind Brewer didn’t have a healthcare background, which in the end proved to be a detriment to the corporate. Whereas Wentworth’s method might trigger some momentary rising pains, he understands the way to proper the ship for the lengthy haul.
One other thrilling change for Walgreens is its aforementioned shift to healthcare companies. Although it’s a bit tardy constructing out its healthcare-service operations, its funding in and partnership with VillageMD ought to show worthwhile within the years to return.
The differentiator right here is that Walgreens is working full-service well being clinics. Whereas most pharmacy chains can do not more than administer a vaccine or deal with a sniffle, VillageMD’s clinics which might be co-located in Walgreens’ shops have physicians on-site. Constructing a base of loyal sufferers ought to steadily develop this new income stream for Walgreens.
Walgreens Boots Alliance additionally hasn’t been shy about spending on varied digital development initiatives. It’s leaned on digitization to enhance the effectivity of its provide chain, in addition to beef up its direct-to-consumer phase. Whereas Walgreens will proceed to generate the majority of its income from its bodily areas, bolstering its on-line gross sales and making issues handy for customers is a straightforward solution to carry its natural development fee.
Price-cutting is taking part in a job, too. After reaching a cumulative $2 billion in diminished annual working bills by the top of fiscal 2021, the corporate is now concentrating on $4.1 billion in combination annual price reductions by the top of the present fiscal yr. This could present a lift to the corporate’s margins, in addition to EPS.
The ultimate piece of the puzzle is that Walgreens Boots Alliance is grime low cost. Shares might be added by opportunistic traders for lower than 6 instances forward-year earnings. This can be a 28% low cost to its common forward-year a number of over the past 5 years, and one heck of a cope with a 5.5% dividend yield in tow.
